InSitu Biologics

United States · Biotech

Biotechnology company developing localized, sustained-release drug delivery, with INSB200 as its lead candidate for post-surgical pain management.

Product

InSitu Biologics is developing a drug-delivery platform designed to retain a therapy near an injection site and release it over several days. Its lead candidate, INSB200, targets post-surgical pain through a peripheral nerve-block injection.

The company is pursuing a non-opioid approach intended to extend localized pain relief while limiting systemic exposure. It plans an investigational new drug submission in the first quarter of 2027 and a Phase 1/2 trial in the second quarter, making clinical development the next step for the candidate.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Convertible note financing$1.3MParticipants not disclosed
Sourcesinsitubiologics.com ↗insitubiologics.com ↗